Current Report Filing (8-k)
December 04 2017 - 5:27PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): December 1, 2017
RICH
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
NEVADA
|
|
000-54767
|
|
46-3259117
|
(State
or other jurisdiction of
incorporation or organization)
|
|
Commission
file number
|
|
(IRS
Employer
Identification
No.)
|
9595
Wilshire Blvd, Suite 900
Beverly
Hills, CA 90212
(Address
of principal executive offices)
(424)
230-7001
(Registrant’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
◻
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
◻
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
◻
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
◻
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SECTION 1 – Registrant’s Business
and Operations
Item
1.01 Entry Into a Material Definitive Agreement
On December 1, 2017, Rich Pharmaceuticals,
Inc. (the “Company”) extended the Employment Agreement for a one-year term with Ben Chang, the Company’s Chief
Executive Officer. The foregoing is only a brief description of the material terms of the Employment Agreement and does not purport
to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their
entirety by reference to the agreements and their exhibits which are filed as an exhibit to this Current Report.
SECTION 5 – Corporate Governance and
Management
Item 5.02
Appointment of Principal Officers; Compensatory Arrangements of Certain Officers
The disclosure in Item 1.01 regarding the Employment
Agreement for Ben Chang is incorporated herein by reference.
On December 1, 2017, the Board of Directors
of the Company extended Ben Chang’s Employment Agreement as the Chief Executive Officer of the Company.
SECTION 9 – FINANCIAL STATEMENTS AND
EXHIBITS
Item
9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
RICH
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
Dated:
December 4, 2017
|
|
|
|
By:
|
|
/s/ Ben
Chang
|
|
|
|
|
|
|
|
|
Ben
Chang
Chief
Executive Officer
|